Dentsply Sirona Appoints Two Highly Experienced Directors to Bolster "Return-to-Growth" Strategy
XRAY sits 33% above its 52-week low of $9.85.
Summary
Dentsply Sirona has expanded its Board of Directors from 11 to 13 members, appointing James D. Forbes and Brian P. McKeon, both bringing extensive financial and strategic expertise to support the company's "Return-to-Growth" action plan.
Key Events · Executive and Board Changes · XRAY
-
Board Expansion and New Appointments
The Board of Directors increased from 11 to 13 members, with James D. Forbes and Brian P. McKeon appointed as new directors, effective February 27, 2026.
-
Strategic Expertise Added
Mr. Forbes brings 30 years of healthcare investment banking, M&A, and capital allocation experience, while Mr. McKeon offers 25 years as a public company CFO with deep financial and operational expertise.
-
Support for "Return-to-Growth" Plan
These appointments are intended to strengthen the Board's strategic, financial, and governance capabilities to execute the company's "Return-to-Growth" action plan, building on the recent appointment of Don Zurbay.
-
Director Retirement
Willie A. Deese will not seek re-election at the upcoming annual meeting, a decision not resulting from any disagreement with the company.
Analysis · XRAY · Industrial Applications And Services
The appointment of two highly experienced directors, James D. Forbes (healthcare investment banking, M&A, capital allocation) and Brian P. McKeon (public company CFO, operational, governance), significantly strengthens Dentsply Sirona's Board. This move, following a recent board appointment, is explicitly tied to enhancing the Board's capabilities to execute the company's "Return-to-Growth" action plan. Their combined expertise is expected to improve strategic oversight, financial rigor, and capital deployment, which are critical for the company's stated growth objectives. The retirement of Willie A. Deese is noted as a non-disagreement departure, making the overall board changes a positive signal for strategic direction and governance.
At the time of this filing, XRAY was trading at $13.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $9.85 to $19.27. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.